Identification and validation of biomarkers related to mismatch repair for prognosis prediction in glioma
-
By
-
Jia Feng
-
Yuankai Si
-
Long Han
-
Yilan Huang
-
Longyang Jiang
-
June 23, 2026
-
Clinical Scorecard: Discovery and validation of mismatch repair-associated biomarkers for prognostic prediction in glioma
At a Glance
| Category | Detail |
|---|
| Condition | Glioma |
| Key Mechanisms | Mismatch repair (MMR) deficiency influences glioma initiation, advancement, and treatment efficacy. |
| Target Population | Patients diagnosed with glioma. |
| Care Setting | Neuro-oncology |
Key Highlights
- Prognostic model developed based on eight MMR-related genes.
- High-risk patients showed significantly diminished overall survival.
- MCM8 identified as a potential target for temozolomide (TMZ) therapy.
- Distinct immune infiltration and tumor microenvironment profiles across risk categories.
- In vitro studies confirmed MCM8's role in TMZ sensitivity.
Guideline-Based Recommendations
Diagnosis
- Utilize MMR-associated biomarkers for prognostic assessment in glioma.
Management
- Consider MCM8 expression levels when planning TMZ-based therapies.
Monitoring & Follow-up
- Assess immune microenvironment and tumor mutational burden in glioma patients.
Risks
- Monitor for TMZ resistance associated with MMR pathway alterations.
Patient & Prescribing Data
Glioma patients, particularly those with MMR deficiencies.
MCM8 overexpression enhances sensitivity to TMZ, while its depletion reduces sensitivity.
Clinical Best Practices
- Incorporate MMR status in the prognostic evaluation of glioma patients.
- Utilize a risk score model for stratifying glioma patients based on survival outcomes.
- Conduct regular assessments of immune cell infiltration in glioma treatment planning.
Related Resources & Content
